12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Aubagio teriflunomide: Additional Phase III data

Additional data from the double-blind, international Phase III TOWER trial in 1,169 patients with relapsing MS showed that once-daily 7 and 14 mg oral Aubagio each significantly increased the proportion of patients who were relapse-free vs. placebo. Specifically, 55% of patients receiving low-dose Aubagio (p=0.0016) and 52% of patients receiving high-dose Aubagio (p<0.0001) were relapse-free vs....

Read the full 257 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >